Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Two New Dividend Picks To Help You Navigate Tariffs And Uncertainty -- One Yields 7%+
03:00pm, Tuesday, 15'th Apr 2025
The acquisitions of Alexandria Real Estate and Unilever enhance sector and geographical diversification, increase dividend income capacity, and reduce portfolio volatility, aligning with The Dividend
Johnson & Johnson tops Wall Street expectations in Q1
01:03pm, Tuesday, 15'th Apr 2025
Johnson & Johnson (JNJ) reported stronger-than-expected earnings. Goldman Sachs Global Investment Research head of the healthcare business unit Asad Haider joins Catalysts with Madison Mills and Stone
Johnson & Johnson (JNJ) Q1 2025 Earnings Call Transcript
12:42pm, Tuesday, 15'th Apr 2025
Johnson & Johnson (NYSE:JNJ ) Q1 2025 Earnings Conference Call April 15, 2025 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joaquin Duato - Chairman and Chief Exec
JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal
12:15pm, Tuesday, 15'th Apr 2025
J&J beats first-quarter earnings and sales estimates. It raises sales guidance for 2025 to reflect the addition of Caplyta from the Intra-Cellular acquisition.
Import Prices Turn Negative for First Time Since September
12:05pm, Tuesday, 15'th Apr 2025
New economic data is out this morning, some of it reflecting conditions prior to our current tariff realities. We also see Q1 earnings results continue to ramp up, but we won't have the spigots open c
Import Prices, Empire State Come In Mild; Q1 Earnings Beats Abound
11:21am, Tuesday, 15'th Apr 2025
Pre-markets are down somewhat, following yesterday's +3/4-percent gain on the Dow and the S&P 500, +2/3-percent gain for the Nasdaq.
J&J Expects Tariffs to Cost Company $400 Million
11:06am, Tuesday, 15'th Apr 2025
Johnson & Johnson is holding its earnings outlook steady despite President Donald Trump signaling he could put tariffs on the pharmaceutical industry. The administration announced earlier it would con
Johnson & Johnson beats on top and bottom lines
10:53am, Tuesday, 15'th Apr 2025
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss J&J's most recent earnings report.
Johnson & Johnson: First Look At Q1 Earnings - Solid Quarter Will Calm Nerves
10:43am, Tuesday, 15'th Apr 2025
Johnson & Johnson's Q1 2025 earnings show a 2.4% sales increase and a significant EPS rise, despite litigation charges impacting GAAP figures. The MedTech division grew 4.1%, driven by acquisitions, w
Compared to Estimates, Johnson & Johnson (JNJ) Q1 Earnings: A Look at Key Metrics
10:31am, Tuesday, 15'th Apr 2025
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics
JNJ Raises Guidance Despite Tariffs, ACI Guidance Slump, GM Downgrades
10:30am, Tuesday, 15'th Apr 2025
Johnson & Johnson (JNJ) boosted its full-year guidance while taking tariffs into account. Diane King Hall talks about its new acquisitions as a reason behind company confidence.
Johnson & Johnson tops Q1 expectations, lifts 2025 sales outlook
09:43am, Tuesday, 15'th Apr 2025
Johnson & Johnson (NYSE:JNJ) reported its first quarter earnings, with both revenue and profit beating Wall Street expectations driven by strong sales in its oncology portfolio, especially the multipl
Johnson & Johnson Skids Despite First-Quarter Beat, Sales Guidance Hike
08:49am, Tuesday, 15'th Apr 2025
Johnson & Johnson stock fell alongside the broader market, despite beating first-quarter calls and hiking its 2025 sales guidance.
Johnson & Johnson (JNJ) Q1 Earnings and Revenues Beat Estimates
08:35am, Tuesday, 15'th Apr 2025
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.71 per share a year ago.
Johnson & Johnson raised its sales outlook, even with tariff costs included
08:11am, Tuesday, 15'th Apr 2025
Johnson & Johnson beat Wall Street's expectations for first-quarter profit and revenue on Tuesday, as strong growth in the U.S. offset weakness internationally.
